Pharma & Biotech Strategy: RWE, Patent Cliffs, & M&A for 2028 Growth
Explore how pharma & biotech firms use RWE, value‑based contracts, and strategic M&A to beat patent cliffs, boost reimbursement speed, and grow revenue.
3 minutes to read
DAIICHI SANKYO CO LTD
DS Secures EU Boost: Enhertu’s Early‑Stage HER2 Approval Sets New Oncology Milestone
EU approval of Enhertu gives Daiichi Sankyo a breakthrough 50% IDFS advantage for early‑stage HER2‑positive breast cancer, unlocking €144 m potential sales and a new oncology frontier.
4 minutes to read
Japanese Equities Rebound: Tech, Finance Surge While Pharma Shares Slide, New Endometrial Cancer Drug Shows Promise
Japanese equities rebound, tech and banks surge; Daiichi Sankyo drops market‑wide. Meanwhile NYU‑led trial shows sacituzumab tirumotecan boosts survival in endometrial cancer.
3 minutes to read
How AstraZeneca’s Dual‑Targeted Oncology Wins Could Reshape the Market in 2028
Explore AstraZeneca’s dual‑targeted oncology breakthroughs—Sone‑Ve and SAFFRON—showing how biomarker‑driven therapies could reshape gastric and lung cancer treatment and market dynamics.
5 minutes to read
Japan’s Daiichi Sankyo Advances Mesothelioma ADC and DLL3 BiTE Trials Toward New Oncology Breakthroughs
Japanese trials show early safety and 40% disease control for DLL3‑BiTE in SCLC, while a novel mesothelin ADC enters phase II, highlighting Daiichi Sankyo’s next‑gen immuno‑oncology strategy.
3 minutes to read
Actinium’s HER3‑Targeted Radiotherapy ATNM‑400 to Debut at 2026 ESMO Congress, A Game‑Changer for mCRPC
Actinium Pharma’s first‑in‑human Phase 1 results for HER3‑targeted ATNM‑400, unveiled at ESMO, could open a new alpha‑therapy path for metastatic prostate cancer.
4 minutes to read